You are here

FDA Issues Approvable Letter for Doxazosin Mesylate

FORT LAUDERDALE, Fla., Jun 21, 2004 (BUSINESS WIRE) -- Andrx Corporation ("Andrx" or "Company") (Nasdaq:ADRX) today announced that the United States Food and Drug Administration ("FDA") has issued an approvable letter for Pfizer Inc.'s ("Pfizer") New Drug Application ("NDA") for Cardura(R) XL, a sustained-release formulation of doxazosin mesylate, used to treat benign prostatic hyperplasia (BPH). As previously announced, Andrx will receive exclusive distribution rights to Cardura XL in the United States upon the approval of the product with certain minimum claims. The FDA's approvable letter sets out the conditions that must be met before final marketing approval is obtained. Pfizer has responsibility for the NDA and has informed us that it intends to respond promptly to the conditions of the approvable letter.

Source: Andrx Corporation

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission